- Home
- GBLI vs ATXS Comparison
GBLI vs ATXS Comparison
Compare GBLI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- ATXS
- Stock Information
- Founded
- GBLI 2016
- ATXS 2008
- Country
- GBLI United States
- ATXS United States
- Employees
- GBLI N/A
- ATXS N/A
- Industry
- GBLI Property-Casualty Insurers
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- GBLI Finance
- ATXS Health Care
- Exchange
- GBLI Nasdaq
- ATXS Nasdaq
- Market Cap
- GBLI 498.5M
- ATXS 584.1M
- IPO Year
- GBLI 2003
- ATXS 2015
- Fundamental
- Price
- GBLI $35.82
- ATXS $9.56
- Analyst Decision
- GBLI
- ATXS Strong Buy
- Analyst Count
- GBLI 0
- ATXS 5
- Target Price
- GBLI N/A
- ATXS $28.00
- AVG Volume (30 Days)
- GBLI 6.5K
- ATXS 346.7K
- Earning Date
- GBLI 11-07-2024
- ATXS 11-13-2024
- Dividend Yield
- GBLI 3.91%
- ATXS N/A
- EPS Growth
- GBLI 90.04
- ATXS N/A
- EPS
- GBLI 2.92
- ATXS N/A
- Revenue
- GBLI $442,500,000.00
- ATXS N/A
- Revenue This Year
- GBLI N/A
- ATXS N/A
- Revenue Next Year
- GBLI $8.39
- ATXS N/A
- P/E Ratio
- GBLI $12.28
- ATXS N/A
- Revenue Growth
- GBLI N/A
- ATXS N/A
- 52 Week Low
- GBLI $27.47
- ATXS $6.20
- 52 Week High
- GBLI $37.00
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- GBLI 52.93
- ATXS 42.48
- Support Level
- GBLI $33.81
- ATXS $9.17
- Resistance Level
- GBLI $36.38
- ATXS $9.99
- Average True Range (ATR)
- GBLI 0.70
- ATXS 0.60
- MACD
- GBLI -0.11
- ATXS -0.02
- Stochastic Oscillator
- GBLI 67.22
- ATXS 21.20
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.